We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prenatal Hormone Levels Linked to Gestational Diabetes Risk

By LabMedica International staff writers
Posted on 17 Sep 2013
Overweight women with low levels of the hormone adiponectin prior to pregnancy are nearly seven times more likely to develop gestational diabetes.

Gestational diabetes, or glucose intolerance during pregnancy, is common and can lead to adverse outcomes including larger-than-normal babies and subsequent delivery complications.

Scientists at the Kaiser Permanente Northern California (Oakland, CA,USA) retrospectively identified about 4,000 women who gave voluntary blood samples between 1985 and 1996 during routine care and subsequently delivered an infant. More...
Among that group, 256 women developed gestational diabetes during pregnancy and 497 did not.

The investigators examined examine whether circulating total and high–molecular weight (HMW) adiponectin concentrations, measured before pregnancy, are associated with subsequent risk of gestational diabetes mellitus (GDM). They found that normal-weight women with low levels of adiponectin were 3.5 times more likely to develop gestational diabetes than their normal-weight peers with normal levels of the hormone.

Additionally, overweight women with high levels of adiponectin were 1.7 times as likely to develop gestational diabetes during pregnancy, while those with the lowest levels were 6.8 times more likely. The combined effects of having total adiponectin levels below the median of less than 10.29 mg/mL and being overweight or obese were associated with a sevenfold increased risk of GDM compared with normal-weight women with adiponectin levels above the median.

Monique M. Hedderson, PhD, the principal investigator of the study, said, “Our findings indicate important pregnancy interventions may be possible before a woman even conceives. Adiponectin levels are easy and inexpensive to measure and could potentially be used to identify women who are at risk for gestational diabetes." The study was published on August 29, 2013, in the journal Diabetes Care.

Related Links:

Kaiser Permanente Northern California



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.